Tag Archives: Vamil Divan

Teva loses four patents on Copaxone; alright, what’s the good news?

The News: A US court invalidated four patents covering Teva Pharmaceutical Industries Ltd.’s (Petach Tikva ISR) three-times weekly version of Copaxone (glatiramer acetate) based on obviousness, following a challenge by… Read more »

Good News for Mylan after Hellish Week: Another Win in Patent War Over MS Drug; Lawyers on Both Sides Rejoice.

Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) had a third patent on its top-selling multiple sclerosis drug, Copaxone, invalidated last Thursday by a U.S. agency, a further blow to its… Read more »

Pfizer Earnings Exceed Estimates; Company Raises 2016 Forecast

Pfizer Inc. (New York), which last month abandoned its $160 billion quest for Allergan PLC (Dublin IRL), reported quarterly results that blew past analysts’ estimates on sales of its new… Read more »